Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease

Trial Profile

Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Sodium phenylbutyrate/tauroursodeoxycholic acid (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms PEGASUS
  • Sponsors Amylyx Pharmaceuticals
  • Most Recent Events

    • 28 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 18 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
    • 26 Jul 2018 Trial design presented at the Alzheimer's Association International Conference 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top